A STUDY TO ASSESS METABOLIC SYNDROME AS A RISK FOR CARCINOMA BREAST: AN OBSERVATIONAL SYUDY

Abstract

Aim and objectives: To assess metabolic syndrome as a risk for Carcinoma Breast. Material and methods: Study was performed in 50 new histologically confirmed breast cancer patients, either pre- or post-menopausal. All patients underwent assessment of anthropometric parameters and laboratory testing. Results: Metabolic syndrome was present in 64% of the patients, indicating that more than half of the study population was affected. The remaining 36% did not have metabolic syndrome. This distribution shows a higher prevalence of metabolic syndrome among the patients of carcinoma breast. Patients with MS in breast cancer patients had a significantly higher body weight (mean 68.28 kg) compared to those without MS (mean 58.89 kg, p<0.001). Similarly, BMI is higher in the MS group (mean 28.52) in breast cancer patients than in the non-MS group (mean 24.03, p<0.001). Waist circumference (mean 97.31 cm vs. 85.28 cm, p<0.001) and hip circumference (mean 115.13 cm vs. 107.61 cm, p<0.001) were also significantly larger in patients with MS in breast cancer patients. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were significantly elevated in patients with MS in breast cancer patients. Fasting plasma glucose levels were significantly higher in the MS group (mean 141.19 mg/dL) in breast cancer patients compared to the non-MS group (mean 96.94 mg/dL, p<0.001) in breast cancer patients. Serum triglyceride levels were also elevated in patients with MS (mean 191.66 mg/dL) versus those without MS (mean 136.94 mg/dL, p<0.001) in breast cancer patients. Although HDL-C levels were slightly lower in the MS group (mean 47.94 mg/dL) in breast cancer patients compared to the non-MS group (mean 53.83 mg/dL), this difference was not statistically significant (p=0.15).